1. Angiotensin II stimulates protein kinase D-dependent histone deacetylase 5 phosphorylation and nuclear export leading to vascular smooth muscle cell hypertrophy
- Author
-
Angelika Hausser, Weiye Wang, Timothy A. McKinsey, Xiangbin Xu, Zheng Gen Jin, Chang Hoon Ha, Eric N. Olson, Klaus Pfizenmaier, and Chelsea Wong
- Subjects
Male ,medicine.medical_specialty ,Vascular smooth muscle ,Myocytes, Smooth Muscle ,Aorta, Thoracic ,Biology ,Histone Deacetylases ,Article ,Muscle hypertrophy ,Rats, Sprague-Dawley ,Internal medicine ,medicine ,Animals ,Protein kinase A ,Protein kinase C ,Protein Kinase C ,Histone deacetylase 5 ,Angiotensin II ,Hypertrophy ,Rats ,Endocrinology ,cardiovascular system ,Phosphorylation ,Protein kinase D1 ,Cardiology and Cardiovascular Medicine ,Protein Kinases ,Signal Transduction - Abstract
Background— Angiotensin II (Ang II) induces the phenotypic modulation and hypertrophy of vascular smooth muscle cells (VSMCs), which is implicated in the pathogenesis of hypertension, atherosclerosis, and diabetes. In this study, we tested the hypothesis that histone deacetylases 5 (HDAC5) and its signal pathway play a role in Ang II-induced VSMC hypertrophy. Methods and Results— VSMCs were isolated from the thoracic aortas of male Sprague-Dawley rats and treated with Ang II. We found that Ang II rapidly stimulated phosphorylation of HDAC5 at Serine259/498 residues in a time- and dose- dependent manner. Ang II receptor-1, protein kinase C, and protein kinase D1 (PKD1) mediated HDAC5 phosphorylation. Furthermore, we observed that Ang II stimulated HDAC5 nuclear export, which was dependent on its PKD1-dependent phosphorylation. Consequently, both inhibiting PKD1 and HDAC5 Serine259/498 to Alanine mutant significantly attenuated Ang II-induced myocyte enhancer factor-2 (MEF2) transcriptional activity and protein synthesis in VSMCs. Conclusion— These findings demonstrate for the first time that PKD1-dependent HDAC5 phosphorylation and nuclear export mediates Ang II-induced MEF2 activation and VSMC hypertrophy, and suggest that PKD1 and HDAC5 may emerge as potential targets for the treatment of pathological vascular hypertrophy.
- Published
- 2007